

Recurrence of Hydroxyurea-induced Leg Ulcer After Discontinuation of Treatment

Kazuhiro Kikuchi¹, Ken Arita¹, Yasuki Tateishi¹, Masahiro Onozawa², Masashi Akiyama¹ and Hiroshi Shimizu¹

Departments of ¹Dermatology and ²Hematology, Hokkaido University Graduate School of Medicine, North 15 West 7, Kita-ku, Sapporo 060-8638, Japan.

E-mail: kikku@med.hokudai.ac.jp

Accepted November 1, 2010.

Hydroxyurea (HU) is a hydroxylated derivative of urea that has been recognized since 1960 as effective against cancer (1). It is an inhibitor of cellular DNA synthesis, and it promotes cell death in the S phase of the cell cycle through inhibition of the enzyme ribonucleotide reductase (2). The most common indications for HU therapy are chronic myeloid leukaemia and other myeloproliferative disorders (3, 4) such as essential thrombocythemia (5) and polycythemia vera (PV) (6). Cutaneous side-effects, such as alopecia, diffuse hyperpigmentation, scaling, lichen planus-like lesions, poikiloderma, atrophy of the skin and subcutaneous tissues, and nail changes, can occur during the treatment with HU (7–9). The occurrence of painful leg ulcers represents another rare and incompletely characterized complication that has been described in patients with myeloproliferative diseases receiving high-dose long-term HU treatment (10). While the mode of action of HU on bone marrow elements is well established, its effects on actively proliferating epithelial cells remain less described (11). Poor response to traditional local and systemic therapy is a typical feature of HU-induced leg ulcers, and discontinuation of the drug is often required to achieve complete wound healing (6, 8). Cessation of the drug usually improves the skin ulcer; although, in some cases, the ulcer remains and additional therapies, such as skin grafting, are needed (12). We report here the first case of a leg ulcer that recurred even after discontinuation of HU treatment.

CASE REPORT

The patient was an 82-year-old Japanese male who had been diagnosed with PV 9 years before and had been treated only with phlebotomy and an anti-platelet agent for several years. Due to splenomegaly and elevated blood cell counts, HU therapy was started 3 years ago at a dosage of 1 g daily for a month, followed by 1.0 or 1.5 g daily for 28 months. A good clinical response was achieved. However, the patient developed painful ulcers on the left second toe after two years of HU treatment.

He visited our outpatient clinic and was diagnosed with an HU-induced skin ulcer. HU was discontinued, topical application of sulfadiazine silver was performed, an oral antibiotic (cefdinir) was administered, and the ulcer epithelialized. However, a new ulcer appeared on the left lateral malleolar area 46 days after cessation of HU and gradually enlarged in size. The patient was admitted to our hospital for treatment of the ulcer.

Examination revealed a 48 × 56 mm ulcer with yellow necrotic tissue and marginal erythematous oedema (Fig. 1). Laboratory examination revealed a white blood cell count of $11.6 \times 10^3/\mu\text{l}$, a platelet count of $64.2 \times 10^4/l$, and a red blood cell count of $5.07 \times 10^6/\mu\text{l}$. Anti-nuclear antibody, anti-neutrophilic cytoplasmic antibodies, anti-cardiolipin antibody, and cryoglobulin were negative. A skin biopsy taken from the margin of the ulcer demonstrated leukocytoclastic vasculitis in the upper dermis (Fig. 2). A wound-healing strategy of surgical debridement, intravenous prostaglandin E1 administration, and topical application of beta-fibroblast growth factor, sulfadiazine silver and alprostadil alfadex was started, and the ulcer began to epithelialize. After 4 months, re-epithelialization was complete. The PV was treated with busulfan, achieving a good clinical response.

DISCUSSION

HU is usually well tolerated and has low toxicity (1). However, cutaneous adverse effects such as diffuse hyperpigmentation, brown discoloration of the nails, acral erythema, photosensitization, fixed drug eruption, alopecia, and oral ulceration have been reported (7–9). Stahl & Silber (10) first reported HU-induced skin ulcers in 1985. Montefusco et al. (11) reported



Fig. 1. Left foot with an ulcer on the lateral malleolar area after two months free of hydroxyurea administration. The ulcer was covered with yellow necrotic tissue and surrounded by oedematous erythema.




Fig. 2. Histology of erythema on the margin of the ulcer (haematoxylin-eosin staining). Fibrin deposition on the vascular wall and nucleic debris were evident around small vessels ($\times 100$). (E: epidermis; V: blood vessels; N: neutrophilic nuclear debris).

that, among 200 chronic myeloid leukaemia patients treated with HU, 17 (8.5%) developed leg ulcers. However, they achieved complete resolution or significant improvement after discontinuation of HU therapy (11). HU-induced leg ulcer and complete resolution within several months after drug discontinuation has also been reported in other myeloproliferative disorder, such as PV (6) and essential thrombocythemia (5). In those cases, as in ours, most of the patients had been treated with > 1 g of HU per day for at least one year (8). In the present case, the patient was treated with > 1 g of HU per day for 28 months. The ulcer occurred on his lateral malleolus, which histologically showed leukocytoclastic vasculitis. These features are consistent with previous reports of HU-induced leg ulcer.

From previous reports, the pathogenesis of HU-induced ulceration remains unclear and it may be multifactorial. It has been postulated that ulcers may be the result of: (i) interruption of microcirculation due to leukocytoclastic vasculitis or arterial microthrombi related to platelet dysregulation (13, 14); (ii) cumulative toxicity in the basal layer of the epidermis through inhibition of DNA synthesis (8); and (iii) repeated mechanical injury in areas subject to trauma: a perimalleolar area for instance (15).

In the case described here, a new ulcer developed even after cessation of HU administration. As for the pathogenic mechanism of recurrence, (i) interruption of microcirculation could result from hyperviscosity due to the elevated platelet count (as high as $100 \times 10^4/l$ in one measurement) (13, 14), although no thrombi were observed histologically in the capillaries or small vessels. (ii) The direct cytotoxic effect of HU (8) may

continue even after the withdrawal of the drug, and it may inhibit the repair of (iii) small injuries in the perimalleolar area: the one of the area susceptible to physical trauma (15). These assumptions can be made from the pathogenesis of HU-induced ulcer reported previously (8, 13–15).

To our knowledge, this is the first report of recurrence of HU-related leg ulcer after the discontinuation of medication. The case suggests that it is important to pay careful attention to recurrence even after cessation of HU therapy. Precise, early treatment for microtraumas and small ulcers should be administered to patients with a long history of HU medication.

REFERENCES

- Boyd AS, Neldner KH. Hydroxyurea therapy. *J Am Acad Dermatol* 1991; 25: 518–524.
- Yarbro JW. Mechanism of action of hydroxyurea. *Semin Oncol* 1992; 19: 1–10.
- Goldman JM. Therapeutic strategies for chronic myeloid leukemia in the chronic (stable) phase. *Semin Hematol* 2003; 40: 10–17.
- Rice L, Baker KR. Current management of the myeloproliferative disorders: a case-based review. *Arch Pathol Lab Med* 2006; 130: 1151–1156.
- Demirçay Z, Cömert A, Adigüzel C. Leg ulcers and hydroxyurea: report of three cases with essential thrombocythemia. *Int J Dermatol* 2002; 41: 872–874.
- Bader U, Banyai M, Böni R, Burg G, Hafner J. Leg ulcers in patients with myeloproliferative disorders: disease- or treatment-related? *Dermatology* 2000; 200: 45–48.
- Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. *Blood* 1997; 90: 3370–3377.
- Weinlich G, Schuler G, Greil R, Kofler H, Fritsch P. Leg ulcers associated with long-term hydroxyurea therapy. *J Am Acad Dermatol* 1998; 39: 372–374.
- Daoud MS, Gibson LE, Pittelkow MR. Hydroxyurea dermatopathy: a unique lichenoid eruption complicating long-term therapy with hydroxyurea. *J Am Acad Dermatol* 1997; 36: 178–182.
- Stahl RL, Silber R. Vasculitic leg ulcers in chronic myelogenous leukemia. *Am J Hematol* 1985; 78: 869–872.
- Montefusco E, Alimena G, Gastaldi R, Carlesimo OA, Valesini G, Mandelli F. Unusual dermatologic toxicity of long-term therapy with hydroxyurea in chronic myelogenous leukaemia. *Tumori* 1986; 72: 317–321.
- Kato N, Kimura K, Yasukawa K, Yoshida K. Hydroxyurea-related leg ulcers in a patient with chronic myelogenous leukemia: a case report and review of the literature. *J Dermatol* 1999; 26: 56–62.
- Sirieux ME, Debure C, Baudot N, Dubertret L, Roux ME, Morel P, et al. Leg ulcers and hydroxyurea: forty-one cases. *Arch Dermatol* 1999; 135: 818–820.
- Chaine B, Neonato MG, Girot R, Aractingi S. Cutaneous adverse reactions to hydroxyurea in patients with sickle cell disease. *Arch Dermatol* 2001; 137: 467–470.
- Saravu K, Velappan P, Lakshmi N, Shastry BA, Thomas J. Hydroxyurea induced perimalleolar ulcers. *J Korean Med Sci* 2006; 21: 177–179.

This is an Open Access article licensed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable to the online version of the article only. Distribution for non-commercial purposes only.

Spontaneous Remission of Solitary-Type Infantile Myofibromatosis

Kazuhiro Kikuchi^a Riichiro Abe^a Satoru Shinkuma^a
Erika Hamasaka^a Ken Natsuga^a Hiroo Hata^a
Yasuki Tateishi^a Masahiko Shibata^a Yuki Tomita^a
Yukiko Abe^a Satoru Aoyagi^a Makio Mukai^b
Hiroshi Shimizu^a

^aDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, and ^bDepartment of Pathology, Keio University School of Medicine, Tokyo, Japan

Key Words

Infantile myofibromatosis · Leiomyosarcoma · Solitary type

Abstract

Infantile myofibromatosis is a rare fibrous tumor of infancy. The cutaneous solitary type has typically an excellent prognosis. However, histologically, it is important to rule out leiomyosarcoma, which has a poor prognosis. The low frequency of mitosis was definitive for a diagnosis of infantile myofibromatosis. We present a cutaneous solitary-type case of infantile myofibromatosis. Following incisional biopsy, the tumor remitted spontaneously.

Introduction

Infantile myofibromatosis is a benign fibrous tumor of infancy and was first described by Stout in 1954 [1]. In most cases, it is present at birth, and in 90% of cases, the tumor appears within the first 2 years of life [2, 3]. The prognosis is excellent in the solitary type, which is limited in the skin, muscle, and subcutaneous lesions [2–4]. In contrast, the multicentric form of infantile myofibromatosis, which has visceral involvement, can be life-threatening [4, 5]. The solitary type is usually benign and the recurrence rate is low at 10%. Therefore, surgical excision is recommended [2, 6].

We present a case of a 3-week-old girl showing features of infantile myofibromatosis (solitary type). Excision was performed and no recurrence was detected in 24 months' follow-up.

Case Report

A 3-week-old, otherwise healthy Japanese girl had a solid, red-colored, cutaneous nodule on left shoulder. The nodule had a central concavity with a crust on the surface and measured 20 × 21 mm in diameter (fig. 1).

Physical examination and CT imaging of the head, chest, abdomen and pelvis revealed no additional lesions. No infiltration of the tumor into the muscle was identified by MRI imaging (fig. 2). Incisional biopsy was performed when the patient was 4 months old. The specimen showed multifocal sclerotic dermal nodules. The nodules were composed of spindle cells with round or oval nuclei and eosinophilic cytoplasm. Delicate bundles of eosinophilic fibers separated the cellular aggregates (fig. 3a, b). A diagnosis of infantile myofibromatosis, leiomyoma, leiomyosarcoma, histiocytoma, or other sarcoma was suggested. Spindle cells expressed smooth muscle actin (fig. 3c), but not caldesmon, desmin or S100 protein (not shown). The mitotic figures were very infrequent [6 mitoses per 10 low-power images (40×)]. These results were confirmed to be consistent with infantile myofibromatosis. The tumor gradually regressed until it completely disappeared 24 months after biopsy.

Discussion

Infantile myofibromatosis usually develops at birth or during the first years of life. Chung and Enzinger found the median age at presentation to be 3 months [2]. A slight male predominance among patients with both the solitary and multicentric variants was noted by Wiswell et al. [7]. Most cases of infantile myofibromatosis are solitary nodules, accounting for up to 70% of cases in one study [2], and up to 80% in another series [4]. The prognosis is excellent in the solitary type [2–4]. In the case of solitary-type infantile myofibromatosis, spontaneous regression can be expected [3, 4]. In contrast, a quarter of the cases with the multicentric form may have visceral involvement and can be life-threatening [2, 4, 5]. The solitary type of infantile myofibromatosis is usually benign and is typically found in the dermis, subcutis, or deep soft tissues. The distribution is predominantly on the head, neck, and trunk like our case. Involvement of the extremities is reported to be rare [2]. Solitary infantile myofibromatosis on an upper extremity accounted for only 13.3% in one study of 45 cases [8].

The histologic hallmark of infantile myofibromatosis is an un-encapsulated, well-circumscribed lobule of peripheral spindle cells, which bear a close resemblance to smooth muscle [9, 10]. Often there is a central area of hemangiopericytoma-like small rounded cells surrounding blood vessels [11, 12]. This combination of features gives infantile myofibromatosis its recognizable biphasic appearance, though the hemangiopericytoma-like appearance was not detected in this case. The presence of smooth muscle actin in the spindle cells indicates the diagnosis of infantile myofibromatosis or leiomyosarcoma. Considering the difference in prognosis, it was necessary to rule out leiomyosarcoma [13] in this case. While at least 1 mitotic cell per field in high-power (×200 or ×400) fields is detected in leiomyosarcoma [14], very infrequent mitotic figures [6 mitotic cells per 10 low-power (×40) fields] were observed, which definitively indicated infantile myofibromatosis in this case.

Previously, radical excision had been advocated as the treatment of choice, because it had been believed that the solitary form gave rise to multiple nodules with potential visceral involvement by metastases [15]. However, it is now more probable that the solitary and multicentric forms are distinct entities and that the solitary form remains localized and can regress [15]. Therefore, a wait-and-see approach has been suggested more recently as a treatment option [15]. However, in our patient, the decision was ultimately made to treat with surgical removal to exclude a diagnosis of leiomyosarcoma, which would have had a poor prognosis. The nodule disappeared completely after excision. The course was consistent with previous reports of solitary-type infantile myofibromatosis [2, 4, 15], and supports our histological diagnosis.



Fig. 1. Solid, red-colored subcutaneous nodule with a central concavity on the left shoulder.




Fig. 2. MRI imaging showed the intensity of the nodule was similar to that of muscle. No additional lesions were found and infiltration of the tumor into the muscle was not observed.





Fig. 3. Hematoxylin-eosin stain, original magnification $\times 20$ (a), and $\times 100$ (b). Specimen showed multifocal sclerotic dermal nodules composed of spindle cells and eosinophilic fibers. c Immunological staining of the tumor for α -smooth muscle actin ($\times 100$). Spindle cells express smooth muscle actin.

References

- ▶1 Stout AP: Juvenile fibromatosis. *Cancer* 1954;7:953–978.
- ▶2 Chung EB, Enzinger FM: Infantile myofibromatosis. *Cancer* 1981;48:1807–1818.
- ▶3 Larralde M, Hoffner MV, Boggio P, Abad ME, Luna PC, Correa N: Infantile myofibromatosis: report of nine patients. *Pediatr Dermatol* 2010;27:29–33.
- ▶4 Stanford D, Rogers M: Dermatological presentations of infantile myofibromatosis: a review of 27 cases. *Australas J Dermatol* 2000;41:156–161.
- ▶5 Goldberg NS, Bauer BS, Kraus H, Crussi FG, Esterly NB: Infantile myofibromatosis: a review of clinicopathology with perspectives on new treatment choices. *Pediatr Dermatol* 1988;5:37–46.
- ▶6 Hogan SF, Salassa JR: Recurrent adult myofibromatosis: a case report. *Am J Clin Pathol* 1992;97:810–814.
- ▶7 Wiswell TE, Sakas EL, Stephenson SR, Lesica JJ, Reddoch SR: Infantile myofibromatosis. *Pediatrics* 1985;76:981–984.
- ▶8 Ang P, Tay Y, Walford Y: Infantile myofibromatosis: a case report and review of the literature. *Cutis* 2004;73:229–231.
- ▶9 Dictor M, Elnor A, Andersson T, Fernö M: Myofibromatosis-like hemangiopericytoma metastasizing as differentiated vascular smooth-muscle and myosarcoma. *Am J Surg Pathol* 1992;16:1239–1247.
- ▶10 Granter SR, Badizadegan K, Fletcher CD: Myofibromatosis in adults, glomangiopericytoma, and myopericytoma: a spectrum of tumors showing perivascular myoid differentiation. *Am J Surg Pathol* 1998;22:513–525.
- 11 Weedon D: Tumors and tumor-like proliferations; in Weedon D (ed): *Skin Pathology*, ed 2. Philadelphia, Churchill Livingstone, 2002, pp 767–768.
- ▶12 Variend S, Bax NMA, van Gorp J: Are infantile myofibromatosis, congenital fibrosarcoma and congenital hemangiopericytoma histogenetically related? *Histopathology* 1995;26:57–62.
- ▶13 Fields JP, Helwig EB: Leiomyosarcoma of the skin and subcutaneous tissue. *Cancer* 1981;47:156–169.
- ▶14 Staut AP, Hill WT: Leiomyosarcoma of the superficial soft tissues. *Cancer* 1958;11:844–854.
- ▶15 Toren A, Perlman M, Polak-Charcon S, Avigad I, Katz M, Kuint Y, Rechavi G: Congenital hemangiopericytoma/infantile myofibromatosis: radical surgery versus a conservative ‘wait and see’ approach. *Pediatr Hematol Oncol* 1997;14:387–393.

Provided for non-commercial research and education use.
Not for reproduction, distribution or commercial use.



This article appeared in a journal published by Elsevier. The attached copy is furnished to the author for internal non-commercial research and education use, including for instruction at the authors institution and sharing with colleagues.

Other uses, including reproduction and distribution, or selling or licensing copies, or posting to personal, institutional or third party websites are prohibited.

In most cases authors are permitted to post their version of the article (e.g. in Word or Tex form) to their personal website or institutional repository. Authors requiring further information regarding Elsevier's archiving and manuscript policies are encouraged to visit:


<http://www.elsevier.com/copyright>



ELSEVIER

Contents lists available at ScienceDirect

Biomaterials

journal homepage: www.elsevier.com/locate/biomaterials

A denatured collagen microfiber scaffold seeded with human fibroblasts and keratinocytes for skin grafting

Margit Kempf^{a,1}, Yuki Miyamura^{b,1}, Pei-Yun Liu^a, Alice C.-H. Chen^a, Hideki Nakamura^b, Hiroshi Shimizu^b, Yasuhiko Tabata^c, Roy M. Kimble^a, James R. McMillan^{a,b,*,1}

^aCentre for Children's Burns and Trauma Research (CCBTR), The University of Queensland, Queensland Children's Medical Research Institute, Brisbane, Australia

^bDepartment of Dermatology, Hokkaido University Graduate School of Medicine, Sapporo, Japan

^cDepartment of Biomaterials, Field of Tissue Engineering, Institute for Frontier Medical Sciences, Kyoto University, Japan

ARTICLE INFO

Article history:

Received 31 January 2011

Accepted 9 March 2011

Available online 8 April 2011

Keywords:

Collagen

Dermis

Scaffold

Keratinocyte

Fibroblast

Surface graft

ABSTRACT

Biomaterial scaffolds are categorized into artificial or natural polymers, or combinations of the two. Artificial polymers often undergo serum protein adsorption, elicit foreign body and encapsulation immune responses post-implantation. Large pore bovine electrospun collagen I was therefore screened as a candidate for human keratinocyte and fibroblast cell scaffolds. Human HaCaT keratinocyte and dermal fibroblasts were seeded on electrospun denatured collagen I microfiber (DCM) scaffolds and after 72 h Livedead[®] assays performed to determine adhesive cell, survival and scaffold penetration. Both keratinocytes and fibroblasts attached to and survived on DCM scaffolds, however only fibroblasts migrated over and into this biomaterial. HaCaT keratinocytes remained largely stationary on the scaffold surface in discrete islands of monolayered cells. For this reason, normal human epidermal keratinocyte (NHEK) scaffold interactions were assessed using scanning and transmission electron microscopy (EM) that demonstrated DCM scaffolds comprised networks of interlocking and protruding collagen fibers with a mean diameter of 2–5 μm, with a mean inter-fiber pore size of 6.7 μm (range 3–10 μm) and scaffold thickness 50–70 μm. After 72 h the keratinocytes and fibroblasts on DCM scaffolds had attached, flattened and spread over the entire scaffold with assembly of lamellapodia and focal adhesion (FA)-like junctions. Using transmission EM, NHEKs and HaCaT keratinocytes assembled desmosomes, lamellapodia and FA junctions, however, neither hemidesmosomes nor basal lamina were present. In long term (21 day) co-culture fibroblasts migrated throughout the scaffold and primary keratinocytes (and to a lesser extent HaCaTs) stratified on the scaffold surface forming a human skin equivalent (HSE). *In vivo* testing of these HSEs on immunocompetent (BalbC) and immunodeficient (SCID) excisionally wounded model mice demonstrated scaffold wound biocompatibility and ability to deliver human cells after scaffold biodegradation.

© 2011 Elsevier Ltd. All rights reserved.

1. Introduction

Skin tissue engineering addresses the need for early, permanent coverage of extensive skin injury in burns patients with an insufficient source of autologous skin for grafting [1,2]. Severe burn

injuries require prompt wound closure but are hampered by limited patient donor site area and the high number of separate surgical operations often required to complete treatment [1,2]. In clinical situations in which insufficient donor skin is available, bioengineered skin in the form of cultured keratinocytes or in combination with fibroblasts to form human skin equivalents (HSEs) has allowed a greater expansion of donor surface area than conventional methods [3]. Cultured skin keratinocyte sheets are typically too fragile for transfer *in vitro* for engraftment and are commonly supported by biomaterial scaffolds that mimic specific tissues [4,5]. Such biomimetic scaffolds are classified into either naturally occurring [6–8] or artificial substrates [9] or combinations of the two source materials. We have previously tested artificial polymers that have many favorable properties [9], although

Abbreviations: DCM, Denatured collagen microfiber; NHEK, Normal human epidermal keratinocytes.

* Corresponding author. Centre Children's for Burns and Trauma Research, (CCBTR), Queensland Children's Medical Research Institute (QCMRI), L/4 RCH Foundation Building, Royal Children's Hospital, Herston, Brisbane, QLD 4029, Australia. Tel.: +61 (0) 7 3636 9069; fax: +61 (0) 7 3365 5455.

E-mail address: j.mcmillan@uq.edu.au (J.R. McMillan).

¹ These authors contributed equally to this paper.

unfortunately some polymers have generally not performed up to expectations in the clinical setting [10–11]. Here, we examine the efficacy of a natural polymer scaffold derived from bovine collagen I. Previous biomimetic scaffolds have included freeze dried collagen sponges alone [4], sponges seeded with fibroblasts [12], collagen I scaffolds cross-linked with elastin [13], collagen II scaffolds [14], collagen and artificial polymer mixes [15–17], collagen cross-linked by carbodiimide [18] or electrospun collagen alone [19–21], electrospun collagen with epidermal keratinocytes [22] and scaffolds co-cultured with fibroblasts and keratinocytes [8,23]. The advantages of electrospun denatured collagen microfibrillar (DCM) scaffolds over frozen sponges come from a more homogenous pore structure and closer biomimetic structure to naturally occurring extracellular matrix [23] with pores of 5–10 microns allowing penetration of fibroblasts into the scaffold [24].

An important function of any potential skin substitute is to support the formation of a proper epidermal barrier to limit trans-epidermal water loss, infection and reduce the chances of hypertrophic scarring by speeding wound closure and ultimately patient recovery [25]. While the need to replace the epidermal barrier is paramount, restoration of normal structure and function of dermal tissue architecture is also critical to achieve acceptable cosmetic results [25]. Currently, there are very few skin substitutes that meet all of these criteria; however, recent cultured skin substitutes comprising fibroblast and keratinocyte cells on natural scaffolds meet many graft requirements [3,23]. The use of natural scaffolds patterned in novel ways to support reconstituted HSEs has primarily focused on reducing scar formation in animal wound models [8]. There are currently several animal wound models on which to test engraftment of human bioengineered skin composites onto immunodeficient mice to assess scarring [26]. In this study we have evaluated the use of DCM scaffold for supporting different human keratinocyte and fibroblast cell combinations for the preparation and transplantation of skin grafts from *in vitro* cultures. We have used *in vitro* cell viability assays to assess HaCaT keratinocyte and fibroblast cell attachment, survival, migration and morphology on DCM scaffolds. Due to the limitations of HaCaT cells to stratify in culture we also included primary human keratinocyte containing cultures in ultrastructural and functional HSE grafts studies. The biocompatibility of the DCM scaffold without cells was tested in excisionally wounded immunocompetent mice. In addition, the efficacy of different cell combinations of DCM composite grafts were tested in excisionally wounded immunocompromised SCID mice. Furthermore, the ability of the grafts to deliver live human cells and improve specific wound healing outcomes including reducing wound closure rates, shortening re-epithelialization times, reducing dermal foreign body and encapsulation immune responses and reducing dermal fibrosis was also assessed.

2. Materials and methods

2.1. Preparation of biomaterial

Denatured collagen microfibrillar (DCM) scaffolds were manufactured as previously described using acid extraction techniques [18] and subsequently disinfected/sterilized (using ethanol and UV light sterilization), washed, air dried and vacuum stored until required. Fiber diameter and morphology of the electrospun scaffold were controlled by concentration and molecular weight of the polymer as previously described [21,24,27]. Fiber diameters of 3–10 μm (greater than 3–4 μm) were produced to allow fibroblast cells to migrate into the scaffold [9]. Upon cell inoculation trapped air was removed using a combination of serial ethanol and sterile 0.1M Dulbecco's phosphate buffered saline (PBS) washes. This biomaterial was submerged in DMEM medium (Invitrogen, Gibco, BRL, Carlsbad CA, USA) before seeded with cultures of human fibroblasts or keratinocytes (HaCaT) keratinocyte cell line or primary normal human epidermal keratinocytes (NHEKs) or in combination. Sterilized, dehydrated DCM biomaterial was directly used for immunocompetent BalbC mouse biocompatibility experiments.

2.2. Cell sources

The cells (keratinocytes or fibroblasts) were only seeded on the upper DCM biomaterial surface. Fibroblast cells were sustained in Dulbecco's Modified Eagles Medium (DMEM) medium with 10% Fetal Calf Serum (FCS), penicillin and streptomycin (Gibco/Invitrogen, Mulgrave, Vic, Australia). HaCaT cells a gift from Dr. N. Fusening (German Cancer Research Center, Heidelberg, Germany) [28] were also maintained in DMEM medium (Gibco/Invitrogen, Mulgrave, Vic, Australia). Normal human neonatal foreskin keratinocytes (Cambrex, Walkersville, MD, catalogue number CC-2503) were grown or isolated in KGM I culture medium (Clonetics, MD/Cambrex, Walkersville, MD, USA) until passage 2 or 3 (P2/P3). Alternatively, primary keratinocytes obtained from surgical specimens (with institutional ethical approval) were maintained in SFM medium (Gibco/Invitrogen, Mulgrave, Vic, Australia) and supplemented with EGF and BPE growth factor supplements (as per the manufacturer's instructions). The cells were then trypsinized and stored in 10% DMSO under liquid nitrogen until required. Normal human dermal fibroblasts were obtained from surgical specimens or commercially (Cambrex, Walkersville, MD, catalogue number 1/2F0-C25) and grown in DMEM with 10% FCS (Cambrex, Walkersville, MD) until passage 5 (P5). Cells were then trypsinized and stored in 10% DMSO under liquid nitrogen until required.

To create primary keratinocyte-fibroblast composites that have the ability to form a stratified epidermis in culture, $1 \times 10^5/\text{cm}^2$ fibroblasts were seeded onto a DMEM medium pre-soaked DCM scaffold at day 0 (seeded cells were maintained in place on the DCM by a modified pipette tip used as an insert). From day 1 these cells were maintained in UCMC 160 medium [29] as previously described [23]. Concurrent with fibroblast confluence on the DCM on day 5, $1 \times 10^6/\text{cm}^2$ keratinocytes were directly seeded in UCMC 160 medium onto the scaffold composites to create a bilayered composite (again, using the modified pipette tip as a retainer). At day 6 the insert was removed and the composite was placed into 6 well plates and transferred onto a nylon mesh platform (Mersilene™ Polyester Fiber Mesh, Ethicon, Johnson and Johnson, Langhorne, PA) to maintain it at the air-liquid interface. From day 10 onwards neither progesterone nor EGF growth factors (supplied with UCMC 160 medium) were added to the UCMC 160 medium. Composites were maintained in UCMC 160 until day 26 with a culture medium change at least every 48 h.

2.3. Livedead® cell survival assay

Low passage, HaCaT keratinocytes (<P10) or dermal fibroblasts (<P5) were expanded and maintained in the previously described DMEM culture medium. Cells were trypsinized, counted and 3.5×10^5 cells per cm^2 plated onto pre-prepared DCM substrate. This density has previously been determined to be sufficient for proper seeding of keratinocytes onto grafts [9,30]. Cells were stringently washed 4 times in sterile 0.1M Dulbecco's phosphate buffered saline to removed non-adherent cells and maintained for 72 h on DCM biomaterial. After 72 h, the cell-biomaterial composites were then subjected to the Livedead® fluorescence assay according to the manufacturer's instructions and the numbers of live (green) non-viable/dead (red) cells (either HaCaT keratinocytes or fibroblasts) immediately assessed using an Olympus Fluoview FV300 confocal and IX70 inverted microscope (Olympus, Tokyo, Japan) with a $\times 20$ objective lens. Only attached, live, uniformly green fluorescent cells or typically small, pyknotic red cells were counted. The mean percentage of live (green fluorescent) and pyknotic red (dead) cells were calculated (from $n = 3$ microscope fields of view repeated three times) as a fraction of total cell numbers represented by the presence of counterstained cell nuclei. Statistical analysis was performed between identical control cells grown on tissue culture plastic (TCP) the treatment groups using one way analysis of variance and two sample *t*-tests using the Minitab statistical package (Minitab Incorporated, University of Pennsylvania, Philadelphia, PA, USA) at a *p* value <0.05 or <0.01 showing significant effects.

2.4. Scanning electron microscopy

DCM substrate alone or monocultures of cells on DCM substrate (fibroblasts, HaCaTs or primary keratinocyte) were maintained for 72 h and subsequently fixed in 2% glutaraldehyde for at least 4 h and processed for routine scanning electron microscopy (SEM) as previously described [9]. Briefly, samples were dehydrated in a graded ethanol series, treated twice with isoamyl acetate, critical point CO_2 dried using a Hitachi HCP-2 (Hitachi, Tokyo, Japan) followed by optional platinum-palladium sputter coating in a Hitachi E-1030 (Hitachi, Tokyo, Japan). Specimens were examined using either a Hitachi S-4500 or JEOL 6400F SEM microscope fitted with a digital image capture system (Japan Electron Optical Ltd, Tokyo, Japan). Over 100 surface adherent cells were examined as a representative sample per cell type on the DCM substrate.

2.5. Transmission electron microscopy

Cell monocultures (keratinocytes or fibroblasts) were maintained on films for over 72 h (between 3 and 26 days) and were fixed in 2% glutaraldehyde solution, post-fixed in 1% OsO_4 , dehydrated, and processed for conventional electron microscopic observation according to the methods described by [9]. Semithin sections were cut and stained with Richardson's stain and mounted using cyanoacrylate glue [31,32].




Fig. 1. Both HaCaT keratinocytes (a, c, e) and normal human dermal fibroblasts (b, d, f) exhibited variable cell densities on the same denatured collagen microfiber (DCM) and could adhere and survive under standard cell culture conditions. HaCaT keratinocytes (green cell in a, c, e) exhibited variable-sized islands of cultured cells with very little evidence of cell migration over or penetration into the core of the DCM biomaterial fibers. Small numbers of individual dead keratinocyte or fibroblasts were apparent (highlighted by white circles over dead cells stained red in a–g). Conversely, fibroblasts demonstrated evidence of cell spreading and migration over and penetration within the entire DCM biomaterial (as highlighted by live cell confocal green fluorescent signal being interrupted by non-fluorescent DCM fibers in b, d, f). This is in contrast to uninterrupted staining of cells (HaCaT or fibroblasts, g) maintained on tissue culture plastic (TCP). Scale bar 200 μm. Image analysis of these images produced estimates of over 94% cell viability (and around 5% non viable cells) for both cell types maintained on DCM biomaterial (HaCaTs 94.3%, fibroblasts 93.6% viable). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

Samples were cut, stained with uranyl acetate and lead citrate and viewed under a JEOL 1010 transmission electron microscope at 75–80 kV with digital image capture.


2.6. Assessment of DCM biomaterial wound biocompatibility in immunocompetent mice

These two procedures, experiments 1 and 2 were performed based on a previous protocol [33]. All animal procedures were conducted according to guidelines provided by the appropriate University Biomedical Institutional Animal Ethics Committee under an approved protocol governing the use of experimental animals. For experiment 1, DCM biomaterial was grafted onto two groups ($n = 5$ each) of 6 week old BALB/cA Jcl immunocompetent mice to assess the effect of the DCM scaffold on excisional wounding without the presence of any human cells (DCM treated or control untreated). The mice were anesthetized with an intra peritoneal (i.p.) injection of 50 mg/kg Ketamine/10 mg/kg Xylasil with additional top-up isoflurane anesthetic as required (0.5–2% isoflurane flow rate of O_2 at 0.5–0.75L/min). The dorsal fur was clipped, ethanol cleaned and a 4 mm diameter full-thickness excisional punch biopsy (Provet, Pty Ltd, Australia) wound made through the back skin. A 4 mm punch biopsy disc of DCM biomaterial was placed and secured within the boundary of original excisional wound or left untreated as a control. All the wounds were then immediately dressed with occlusive film (GLAD Wrap ©, Padstow, NSW Australia) to maintain the wound in a moist environment and held in place for 1 week by Fixomull bandage (Smith and Nephew Healthcare, Hull, UK). After 7 days the dressings were removed and the dimensions of each wound were

then digitally photographed and recorded on a daily basis and wound closure rates assessed using image analysis software (Image Pro Plus V9, Media Cybernetics, Bethesda, MD, USA). Wound closure was defined as the point when the epidermal skin surface appeared completely re-epithelialized (closed) with no evidence of underlying tissue such as bodily secretions, exudate or crusted blood. Wound size and closure rates were calculated by converted pixel area to wound area in mm^2 until complete re-epithelialization had taken place (performed in a standardized fashion by one individual). All wounds were repaired within 18 days. After 21 days the mice were sacrificed by CO_2 asphyxiation and the remaining dorsal skin shaved. The centre of each wound was then labeled with indelible (permanent) marker and the biopsy excised with a 20–50 mm border of normal skin (for orientation purposes) processed for histological examination.

2.7. Assessment of DCM cell composites on wound healing in immunosuppressed mice

In mouse experiment 2, we assessed the effects of different combinations of cell-DCM biomaterial composites in our excisionally wounded SCID (C.B-17 Icr-Scid Jcl strain on a BALB/c background) model mice using five groups of 6 week old immunodeficient mice ($n = 5$ per group, 35 in total) were included in this experiment. The mice were prepared and treated as previously described but each group was treated with a different biomaterial composite wound insert. The groups comprised 1) wounded untreated mice, 2) wounded/DCM/nylon Mersilene™ nylon mesh support(mesh) treated mice, 3) wounded/mesh support alone treated



mice and 4) wounded/DCM/mesh/HaCaT/fibroblast and 5) wounded/DCM/mesh/NHEK/fibroblast human skin equivalent treated SCID mice (see previous methods section for details of cell-DCM biomaterial culture). Wounds were dressed for 1 week only and wound closure assessment made from day 7 until complete re-epithelialization. Macroscopic wound photographic results from individual animals and averaged group results of closure rates and total time to wound closure from each treatment group of animals were assessed using image analysis software (Image Pro Plus V9, Media Cybernetics, Bethesda, MD, USA) and displayed graphically. All mice were sacrificed on day 21 and wound biopsies taken for histological assessment as described below.

2.8. Immunohistological wound assessment

Fur-clipped, indelibly marked wounded mouse skin and surrounding, perilesional un wounded skin were removed and either embedded in OCT compound (SAKURA, Torrance, CA) to be snap frozen in liquid nitrogen cooled isopentane or fixed in 4% formaldehyde in phosphate buffered saline, and processed for paraffin embedding for routine H&E and modified Masson's Trichrome stains for histological analysis (to assess wound healing responses, fibrosis and identify areas of neodermis containing newly synthesized collagen). Wounds were assessed by multiple serial sectioning and selection of tissue from the closest point to the center of the wound.

To assess the persistence and migration of human cells delivered into mouse wound tissue from the biomaterial graft in the SCID mouse model we performed indirect immunofluorescence using frozen, unfixed cryostat sections of mouse wounded skin treated with cell-biomaterial composites and normal human skin sections as controls. Briefly, cryostat tissue sections were fixed in acetone and incubated with primary antibody/antisera. Sections were incubated with secondary antibodies conjugated to fluorescein isothiocyanate (FITC; rabbit anti-mouse IgG or goat anti rabbit IgG; 1: 200; Dako, Tokyo, Japan). Sections were then labeled with a 4',6'-diamidino-2-phenylindole (DAPI) nuclear counter stain contained in Vectashield mounting medium (Vectorlabs, Burlingame, CA, USA). The sections were examined with an Olympus Fluoview FV300 confocal microscope (Olympus, Tokyo, Japan) in duplicate. Controls included human skin cryostat sections with the primary antibody substituted by PBS, myeloma supernatant or an irrelevant immunoglobulin isotype, as a negative control. All experiments were performed in duplicate.

2.9. Statistical analysis

For quantitative measurements either the Student's *t*-test for two sample comparison or for multiple comparison ANOVA was performed (Minitab Incorporated, University of Pennsylvania, Philadelphia, PA, USA) at a *P* value < 0.05 or < 0.01 to demonstrate significance.

3. Results

3.1. Livedead® cell assay

The results show that DCM scaffold is able to maintain adhesion and cell survival of both keratinocyte HaCaT cells (Fig. 1a, c, e) and fibroblasts on DCM (Fig. 1b, d, f) in a similarly effective fashion as cells cultured on conventional tissue culture plastic (TCP) (g). There were however, two main differences between keratinocyte and fibroblast migration on DCM compared to TCP. Firstly, keratinocyte cells formed discrete islands over a limited area on the DCM surface suggesting that lateral migration over the surface of DCM is severely limited or completely inhibited compared to fibroblasts (Fig. 1a, c, e versus b, d, and f). Secondly, migration of the primary human fibroblasts into the DCM matrix was much more evident as demonstrated by the pattern of dark 2–5 µm-thick fibers crossing the images obscuring the live (green fluorescent) cells in the center of the DCM biomaterial (Fig. 1b, d, f) compared to the unobscured

keratinocytes (Fig. 1a, c, e). For each cell type the percentage of viable cells (in green) was very high and ranged between (94–96% viability) with HaCaT keratinocyte cells demonstrating a similar mean viability to fibroblasts on DCM (Fig. 1h *p* > 0.05) or compared to HaCaTs maintained on polystyrene TCP (96.2% live see Fig. 1g). Dead cells in the Livedead® assay were shown as small dots stained in red (highlighted by white circles a–g). Due to limitations in HaCaT keratinocyte monolayer cell migration over DCM (shown by their preponderance to remain in small islands) and to induce stratification primary human keratinocytes were included in subsequent experiments.

3.2. Scanning electron microscopy

Gross macroscopic analysis of the DCM biomaterial demonstrated a thin, moderately stiff white, paper-like fibrous biomaterial (Fig. 2a) that became softer and more pliable upon immersion in aqueous solutions. Low power scanning electron microscopy (SEM) of platinum coated samples revealed a complex multilayered fibrous structure comprising a compact network of randomly oriented (non-woven) fibers of various thicknesses ranging in diameter from 2 to 5 µm (mean diameter of 4.3 µm, *n* = 50 fibers) and with variable inter-fiber porosity ranging between 3 and 10 µm (mean 6.7 µm, *n* = 50 fibers). This considerable range in DCM fiber diameter (up to 2.5 fold) coupled with variable porosity are crucial design characteristics of this biomaterial [9,24]. Overall the entire thickness of the DCM biomaterial ranged between 50 and 70 µm (Fig. 2b) and visualization into the upper 10–20 µm layers of fibers of this fibrous sheet was possible in uncoated samples (i.e. without Pt coating, Fig. 2c–e). DCM cell composites demonstrated normal primary human epidermal keratinocyte (NHEK)(Fig. 2f), HaCaT keratinocyte cell line (Fig. 2g) and fibroblast cell (Fig. 2h) attachment and spreading on the fibrous biomaterial surface. Cell membrane processes involved the formation of lamellapodia and putative sites of focal contact formation were observed (see white arrows in Fig. 2f–h).

3.3. Transmission electron microscopy

Semithin sections of normal human skin demonstrated multilayered, keratinizing epidermal layers and bundles of well organized collagen fibers in the dermis (labeled D in Fig. 3a). Plastic embedded, sectioned biomaterial (Fig. 3b) and skin cell-biomaterial composites (Fig. 3c–g) demonstrated that DCM is a good dermal substitute allowing keratinocyte and fibroblast cell adhesion/survival and fibroblast migration over and penetration into the DCM biomaterial. DCM comprised a more amorphous aggregation of randomly distributed and oriented electrospun fibers (Fig. 3b). Despite this, normal primary human epidermal keratinocytes (NHEK) (Fig. 3c), HaCaT keratinocyte cells (Fig. 3d) and normal fibroblasts (Fig. 3e) all adhered directly on to the DCM scaffold. Furthermore, fibroblasts migrated into the DCM when cultured either alone or co-cultured with HaCaT keratinocyte cells (Fig. 3e and f). Co-cultures of HaCaT and fibroblasts on DCM (Fig. 3f), however, failed to form a multilayered, well stratified and keratinized epidermal layer, despite the

Fig. 2. Macroscopic and electron microscopic views of denatured collagen microfibrillar (DCM) biomaterial without seeded cells (a–e) and with seeded skin cells (keratinocytes f, g and fibroblasts h). Macroscopic view of DCM biomaterial reveals a variably stiff but thin white fibrous material resembling a good quality slightly thickened paper sheet that becomes soft and flexible when hydrated (a). Scanning electron microscopy (SEM) of Pt coated DCM shows a dense network of randomly interwoven fibers with a well defined, almost solid surface that upon closer SEM inspection of uncoated samples (hence the DCM biomaterial exhibited some static charging effects) revealed a network of large pores (between 3 and 10 µm mean 6.7 µm) and channels between loose, randomly oriented electrospun DCM fibers 2–5 µm in thickness (c–e) with a mean fiber diameter of 4.3 µm. HaCaT and primary keratinocytes (f and g) and fibroblasts (h) were seeded on DCM and maintained in culture for between 3 and 8 days. Keratinocytes formed small rounded, dome shaped cells with cytoplasmic focal contact projections resembling lamellapodia extending toward the DCM surface. Fibroblasts however, formed longer, thinner elongated cells with fewer, typically 3–4 focal contact like projections at the ends of lamellapodia. Several small sections of fibroblasts were observed protruding from within the DCM channels and pores (data not shown).




Fig. 3. Semithin plastic embedded sections show normal human skin (a) with stratified, keratinized epidermal layers over lying bundles of dermal collagen (labeled as D in a), whereas the structure of DCM scaffold (b) is more amorphous and significantly thinner than human dermal tissue with a thickness of between 50 and 70 μm. Cell-biomaterial composites show that primary keratinocytes (c) HaCaT cells (d) and fibroblasts (e) adhere to DCM scaffolds (b) and can be maintained in culture. Seeded primary (c) and HaCaT (d) keratinocyte monocultures adhere to DCM with the formation of thin multilayered epidermal keratinocytes in culture. Fibroblasts, however, proliferate (more than any of the keratinocyte cell types) over the surface of the DCM and in addition penetrate the porous DCM fibers in culture (e). Co-culture of HaCaT and fibroblast cells led to a loss of epidermal architecture and increases in HaCaT/fibroblast-DCM penetration (f). Conversely, co-culture of primary NHEKs and fibroblasts on DCM over 26 days at the air liquid interface (g) demonstrated remarkable levels of epidermal stratification and differentiation in addition to fibroblast invasion into the DCM substrate. Scale bar 150 μm. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).




Fig. 4. Ultrastructural examination of primary human keratinocytes seeded on DCM showed a multilayered keratinocyte cell sheet attached to an electron dense DCM scaffold. Thin electron dense DCM fiber projections (white arrows in a) were noted between basal keratinocyte cells (Ks) close to the DCM scaffold (DCM). (b) In areas of close keratinocyte cell apposition highlighted by the middle white box in (a) there were cell–cell desmosomal junctions (labeled D) and adherens junctions (AJ). In areas these structures were quite numerous (left hand box in a, shown in c). However, in areas of keratinocyte-DCM apposition (right hand white box in a, shown in d) there were no signs of any hemidesmosomes linking the DCM substratum (d) only lamellapodia (LP) with putative focal contact like junctions.




Fig. 5. Excisionally wounded immunocompetent BalbC model mice showed no difference in mean time to complete wound closure (a) or in the mean rate of wound closure (b) with or without DCM scaffold wound treatment ($n = 5$ each group). Furthermore, the effect of DCM scaffold incorporation into the healing excisional wound failed to induce significant foreign body wound immunoreactivity or scarring response as demonstrated by increases in the mean thickness of either wounded epidermal or dermal tissue (new collagen deposition stains blue see arrows in c and d) in modified Masson's Trichrome stained paraffin embedded mouse skin sections. Individual wound thickness measurements for each of the 5 BalbC mice per group demonstrated no alterations in wound thickness between treatment groups ($p > 0.251$). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

composite being raised to air–liquid interface on mesh supports and the DCM scaffold acting as a dermal substitute for fibroblast invasion. Conversely, co-culture of fibroblast and NHEK cells produced, 4–5 cell multilayered, polarized, well stratified and partially keratinized epidermal-like continuous structure (Fig. 3g). Ultrastructurally, the NHEK keratinocytes on the DCM exhibit good close cell–cell association with the presence of perinuclear keratin filaments (KFs, Fig. 4a) that upon higher magnification reveal closely apposing adjacent keratinocyte plasma membranes (Fig. 4b) with both desmosomal (D) and adherens junction (AJ) like structures on the membrane (Fig. 4c). On the basal border of the basal layer keratinocyte overlying the biomaterial (labeled DCM in Fig. 4d) there is a marked absence of hemidesmosomal cell–matrix junctions but instead there are small membrane like lamellapodia-like processes consistent with the presence of focal contract cell–matrix junctions (LP in Fig. 4d).

3.4. Wounded model mice

Our data show from experiment 1 assessing the biocompatibility of DCM in BalbC mice demonstrated the incorporation of DCM scaffold without cells into wounded mouse tissue on immunocompetent mice has little or no adverse effect on the processes of normal wound healing and subsequent wound closure times in all 5 mice tested in each treatment group (Fig. 5a, $p > 0.05$) and rates of wound closure

(Fig. 5b, $p > 0.05$). There was little difference in wound appearance between each of the different treatment groups with the main difference being slight changes in the rate of wound healing.

Both hematoxylin and eosin (H&E, data not shown) and modified Masson's Trichrome stained paraffin sections of mouse skin (Fig. 5c and d) showed similar re-epithelialization rates (Fig. 5a and b) and levels of skin thickening, 21 days after excisional wounding in both untreated and DCM treated mouse groups (Fig. 5e). Furthermore, there was no statistical difference in combined mean epidermal and dermal wound thickness (suggestive of scarring likelihood) over the excisional wounds themselves at 21 days post wounding (Fig. 5e).

Similarly, in experiment 2 assessing the efficacy of combinations of cell-DCM-scaffold composites in SCID mice there was no difference in mean wound closure times (Fig. 6b, $p > 0.05$) or wound closure rates (Fig. 8) between the 5 treatment groups seeded with or without combinations of human fibroblast and keratinocyte-DCM grafts in our SCID mouse animal model. Normal human skin was used as the positive control from anti-human HLA staining (see asterisks in Fig. 7a) for human cells in mouse wounds. Confocal microscopy using anti-human HLA antibody staining of wounded mouse skin after treatment with 2 of the 5 graft combinations including human cells on DCM scaffold demonstrated that these cells were engrafted into the wounded mouse tissue, survive and were maintained there for up to 21 days post injury (see asterisks in Fig. 7e and f versus Fig. 7b–d).




Fig. 6. Excisionally wounded immunodeficient SCID mice treated with DCM-mesh scaffold seeded with different skin cell combinations showed a significant increase in wound closure time compared to wound only, DCM and mesh treated and mesh treated wounds (a, $n = 5$ mice for each treatment group). There was no difference in the mean time to complete wound closure between the wound only, and the two DCM/mesh/skin cell-treated groups. Assessment of foreign body wound immunoreactivity/acute scarring response by using the mean combined epidermal/dermal tissue thickness (μm) 21 days after wounding demonstrated that the use of plastic mesh to support the graft at the air liquid interface during culture (and its subsequent incorporation into the DCM graft) increased acute wound thickness compared to all other treatments (b). This effect however, could be partially alleviated using DCM/mesh composite seeded with human skin cells (c). Histological analysis of paraffin embedded modified Masson's Trichrome stained wounded mouse skin demonstrated that compared to normal unwounded dermal thickness (c, mean depth $190 \mu\text{m}$), the dermal wound thickness increased more than four fold in the untreated group (b and d), and by significantly more ($p < 0.01$) in the mesh treated group (graph in b and figures c and d versus e). All other wound treatments showed minimal affects on acute phase dermal thickening in the presence of DCM (with or without cells) with concomitant significant reductions in mesh-associated dermal scarring. Scale bar 1 mm or $1000 \mu\text{m}$ (c–h). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

4. Discussion

The material properties of electrospun denatured collagen microfibrillar (DCM) make this a promising candidate scaffold for skin-derived cell grafting. It comprises extracted bovine collagen

and when combined with cells in a composite, avoids adverse foreign body immune responses after grafting more than many typical artificial polymers [9,21,34]. Bovine collagen was easy and cheap to prepare and quick to manufacture on an appropriate scale using a previously described process of acid extraction and




Fig. 7. Excisionally wounded SCID mice demonstrated human keratinocyte and fibroblast cell engraftment and survival in wounded mouse skin after 21 days using anti-human HLA specific antibodies after human cultured cell-DCM composite wound graft treatments. Control human skin stained with anti-human HLA antibody (a) showed bright fluorescence throughout the epidermis (asterisks above the dashed line) and bright patches within dermal tissue (asterisks). Conversely, untreated wounds (b), DCM (c), DCM/mesh only treated (d) mouse skin showed no focal areas of fluorescent staining for human keratinocyte or fibroblasts. However, non-specific reactivity with the antibody stained the hair follicle and shaft in many of these mouse tissues (see arrows in b). Finally, treatment of wounds with human HaCaT-fibroblasts (e) or primary keratinocyte-fibroblast DCM grafts (f) demonstrated significant staining of dermal cell foci (asterisks in e and f) and some epidermal staining (arrowheads in f) highlighting human cell survival and engraftment into the wound. Scale bar 0.3 mm or 300 μm (a–f). (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article).

alcohol/UV sterilization to minimize potential biosafety issues but preserve, as much as possible, the natural collagen protein conformation [21]. Electrospinning was used to produce biomimetic-scaled scaffold fibers similar to dermal collagen fibers specific for this application. Such scaffold fibers mimic the close structural profile of the natural dermal extracellular matrix (ECM) to which the fibroblast and keratinocyte integrin receptors bind [21,35,37]. In addition, this scaffold was predicted and shown to be able to undergo complete hydrolysis during the dermal reorganizational and maturation stages of wound healing to become safely degraded in its target tissue. This avoids the need for the composite to be removed after grafting allowing the wound to remain intact avoiding further damage and subsequent inflammatory processes.

Electrospun collagen provides a porous, dermal-like template for skin cell attachment that allows both keratinocytes and fibroblasts to survive and proliferate and for fibroblasts to penetrate through and migrate over this scaffold *in vitro*. The uncoated DCM scaffold EM data suggest DCM pores average 6–7 μm (ranging from 3 to 10 μm) that are significantly larger than the lower cut-off limit

described for fibroblast penetration and migration (anything smaller than between 4.5 and 5 μm limits fibroblast penetration) [9,24]. Conversely, these large DCM pores do not appear to encourage single cell keratinocyte or cell sheet migration/penetration as seen in fibroblasts. However, it appears that two factors may be able to overcome this reduced keratinocyte migration on DCM; firstly a high initial keratinocyte seeding density and secondly pre-seeding the DCM with live human fibroblasts until confluent. This migration finding was unexpected as keratinocytes failed to assemble hemidesmosomes that encourage stable anchorage to the underlying matrix-scaffold (likely due to the lack of laminin 332) but assembled multiple focal contact associated lamellapodia important in migration. We hypothesize that either cell type releases matrix or utilizes exogenous soluble factors that encourage keratinocyte focal contact adhesion when maintained on DCM scaffolds.

DCM scaffold appears efficient at maintaining cell adhesion and survival (compared to TCP substrates), however these precise adhesion rates are difficult to determine in our experiments since cell proliferation and survival might have affected the results

during the course of the Livedead® experiments. Previous studies have demonstrated that electrospun collagen fibers show reduced keratinocyte adhesion compared to unprocessed collagen or spun collagen fibers coated with ECM substrates [22,35]. In our experiments however, no deficit was noted in keratinocyte adhesion to fibroblast seeded DCM scaffold maintained in culture. These findings may reflect fibroblast cell deposition of new cell-matrix components (collagen I or fibronectin or vitronectin) onto the DCM scaffold before keratinocyte seeding as has been described for other scaffolds [9].

The porous nature of this scaffold and its ability to hold fluid between the fibers by capillary action means that graft survival can at least be temporarily supported by nutrients in wound tissue fluid, in the absence of a viable dermal blood supply. The ability of tissue fluid to support the graft would be made easier with a reduced cellular load in or on the scaffold, perhaps if grafted before complete confluence and/or epidermal maturation has taken place.

Conversely, the large 3-dimensional and variable pore sizes allow the reciprocal movement of both live fibroblast cells and cell-secreted cytokine growth factors into the wound bed to influence the important dermal wound healing processes like neo-vascularization. DCM biomaterial strength allows HSE graft transport and placement directly onto the wound from the *in vitro* cultures, avoiding problems with surgical handling. The random fiber orientation and DCM scaffold composition likely imparts stiffness that means wound contraction is less of an issue compared to other softer polymer materials where graft contraction can significantly limit the original surface area by as much as 20% [36].

Our data from experiment one, the excisional wounded animal model suggests that DCM scaffold alone is non-cytotoxic with dermal tissue and does not induce a foreign body immune response. This is in contrast to previous reports of electrospun fibers that only fail to induce acute foreign body immune responses when grafted with cells including: fibroblasts [34] and fibroblast/keratinocyte combinations in animal wounding models [22]. In the majority of these models the time frame for re-epithelialization to complete was within the critical two week period to reduce the chances of infection and subsequent hypertrophic scarring [22,24,34]. Wounded mouse models exhibit very different wounding time frame and responses from our previously described porcine model of burn wounding [37]. These differences relate to the scale of tissue, wounds and the differential structural composition of mouse skin resulting in healing largely by wound contraction, rather than re-epithelialization.

These factors are also likely to be important when assessing data from experiment two where DCM scaffold overcame the detrimental effects of grafting with the Nylon Mersilene™ mesh culture support with the DCM composite in inhibiting wound closure and promoting dermal thickening (it was included to support the DCM at the air liquid interface during culture to encourage keratinocyte differentiation). In future a better (less disruptive) alternative to mesh support will be identified for supporting scaffold composites, one that is hopefully easier to remove from the composites before grafting or a material that has less influence wound healing than the Nylon Mersilene™ mesh.

5. Conclusions

In conclusion, our data taken together show that DCM scaffold exhibits improved mechanical properties in terms of support and reducing graft shrinkage over unsupported cultured epithelial autografts (CEA) and avoids typical artificial polymer based scaffold immune responses. Furthermore, DCM cultured cell grafts do not require any donor site biopsies avoiding subsequent donor wounds

as split thickness skin grafts procedures do. Further work would be beneficial to optimize keratinocyte adhesion, migration, proliferation and differentiation on DCM biomaterial to further improve its surface characteristics.

Acknowledgments

This work was funded by a New Staff Start-Up Grant from The University of Queensland (JRM), by a grant-in-aid from the Health and Labor Sciences Research Grant (research into specific diseases) H17-Saisei-12 (Japan) and by support from the Brisbane Royal Children's Hospital Foundation (Queensland Children's Medical Research Institute, QCMRI). Author Disclosure Statement: The authors state that no completing financial interests exist.

Appendix. Supplementary data

The supplementary data associated with this article can be found in the on-line version at doi:10.1016/j.biomaterials.2011.03.023.

References

- [1] Tanner Jr JC, Vandeput J, Olley JF. The mesh skin graft. *Plast Reconstr Surg* 1964;34:287–92.
- [2] Warden GD, Saffle JR, Kravitz M. A two-stage technique for excision and grafting of burn wounds. *J Trauma* 1982;22:98–103.
- [3] Boyce ST, Kagan RJ, Greenhalgh DG, Warner P, Yakuboff KP, Palmieri T, et al. Cultured skin substitutes reduce requirements for harvesting of skin autograft for closure of excised, full-thickness burns. *J Trauma* 2006;60:821–9.
- [4] Yannas IV, Burke JF, Orgill DP, Skrabut EM. Wound tissue can utilize a polymeric template to synthesize a functional extension of skin. *Science* 1982;215:174–6.
- [5] MacNeil S. Progress and opportunities for tissue-engineered skin. *Nature* 2007;445:874–80.
- [6] Metcalfe AD, Ferguson MW. Tissue engineering of replacement skin: the crossroads of biomaterials, wound healing, embryonic development, stem cells and regeneration. *J R Soc Interface* 2007;4:413–37.
- [7] Metcalfe AD, Ferguson MW. Bioengineering skin using mechanisms of regeneration and repair. *Biomaterials* 2007;28:5100–13.
- [8] Berthod F, Germain L, Li H, Xu W, Damour O, Auger FA. Collagen fibril network and elastic system remodeling in a reconstructed skin transplanted on nude mice. *Matrix Biol* 2001;20:463–73.
- [9] McMillan JR, Akiyama M, Tanaka M, Yamamoto S, Goto M, Abe R, et al. Small-diameter porous poly (epsilon-caprolactone) films enhance adhesion and growth of human cultured epidermal keratinocyte and dermal fibroblast cells. *Tissue Eng* 2007;13:789–98.
- [10] Geisler HP. *Biomaterials*; 1996:17.
- [11] Vacanti JP, Vacanti CA. In: Diego San, editor. Principles of tissue engineering. 2nd ed. CA, USA: Academic Press (Elsevier); 2000.
- [12] Park SN, Park JC, Kim HO, Song MJ, Suh H. Characterization of porous collagen/hyaluronic acid scaffold modified by 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide cross-linking. *Biomaterials* 2002;23:1205–12.
- [13] Hafemann B, Ghofrani K, Gattner HG, Stieve H, Pallua N. Cross-linking by 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) of a collagen/elastin membrane meant to be used as a dermal substitute: effects on physical, biochemical and biological features *in vitro*. *J Mater Sci Mater Med* 2001;12:437–46.
- [14] Shields KJ, Beckman MJ, Bowlin GL, Wayne JS. Mechanical properties and cellular proliferation of electrospun collagen type II. *Tissue Eng* 2004;10:1510–7.
- [15] Dai NT, Williamson MR, Khammo N, Adams EF, Coombes AG. Composite cell support membranes based on collagen and polycaprolactone for tissue engineering of skin. *Biomaterials* 2004;25:4263–71.
- [16] Dai NT, Yeh MK, Liu DD, Adams EF, Chiang CH, Yen CY, et al. A co-cultured skin model based on cell support membranes. *Biochem Biophys Res Commun* 2005;329:905–8.
- [17] Powell HM, Boyce ST. Engineered human skin fabricated using electrospun collagen-PCL blends: morphogenesis and mechanical properties. *Tissue Eng Part A* 2009;15:2177–87.
- [18] Barnes CP, Pemble CW, Brand DD, Simpson DG, Bowlin GL. Cross-linking electrospun type II collagen tissue engineering scaffolds with carbodiimide in ethanol. *Tissue Eng* 2007;13:1593–605.
- [19] Reneker DH, Yarin AL, Fong H, Koozhongse S. Bending instability of electrically charged liquid jets of polymer solutions in electrospinning. *J Appl Phys* 2000;87:4531–47.
- [20] Reneker DH, Chun I. Nanometre diameter fibres of polymer, produced by electrospinning. *Nanotechnology* 1996;7:216–23.

- [21] Matthews JA, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen nanofibers. *Biomacromolecules* 2002;3:232–8.
- [22] Rho KS, Jeong L, Lee G, Seo BM, Park YJ, Hong SD, et al. Electrospinning of collagen nanofibers: effects on the behavior of normal human keratinocytes and early-stage wound healing. *Biomaterials* 2006;27:1452–61.
- [23] Powell HM, Supp DM, Boyce ST. Influence of electrospun collagen on wound contraction of engineered skin substitutes. *Biomaterials* 2008;29:834–43.
- [24] Powell HM, Boyce ST. Fiber density of electrospun gelatin scaffolds regulates morphogenesis of dermal-epidermal skin substitutes. *J Biomed Mater Res A* 2008;84:1078–86.
- [25] Klingenberg JM, McFarland KL, Friedman AJ, Boyce ST, Aronow BJ, Supp DM. Engineered human skin substitutes undergo large-scale genomic reprogramming and normal skin-like maturation after transplantation to athymic mice. *J Invest Dermatol* 2010;130:587–601.
- [26] Gawronska-Kozak B, Bogacki M, Rim JS, Monroe WT, Manuel JA. Scarless skin repair in immunodeficient mice. *Wound Repair Regen* 2006;14:265–76.
- [27] Matthews JA, Boland ED, Wnek GE, Simpson DG, Bowlin GL. Electrospinning of collagen type II: a feasibility study. *J Bioact Compat Polym* 2003;18:125–34.
- [28] Boukamp P, Petrussevska RT, Breitkreutz D, Hornung J, Markham A, Fusenig NE. Normal keratinization in a spontaneously immortalized aneuploid human keratinocyte cell line. *J Cell Biol* 1988;106:761–71.
- [29] Swope VB, Supp AP, Greenhalgh DG, Warden GD, Boyce ST. Expression of insulin-like growth factor I by cultured skin substitutes does not replace the physiologic requirement for insulin in vitro. *J Invest Dermatol* 2001;116:650–7.
- [30] Butler CE, Orgill DP, Yannas IV, Compton CC. Effect of keratinocyte seeding of collagen-glycosaminoglycan membranes on the regeneration of skin in a porcine model. *Plast Reconstr Surg* 1998;101:1572–9.
- [31] Richardson KC, Jarret L, Finke EH. Embedding in epoxy resins for ultrathin sectioning in electron microscopy. *Stain Technol* 1960;35:313–23.
- [32] Liu PY, Phillips GE, Kempf M, Cuttle L, Kimble RM, McMillan JR. Cyanoacrylate glue as an alternative mounting medium for resin-embedded semithin sections. *J Electron Microscop* (Tokyo) 2009;59:87–90.
- [33] Zhao Y, Shimizu T, Nishihira J, Koyama Y, Kushibiki T, Honda A, et al. Tissue regeneration using macrophage migration inhibitory factor-impregnated gelatin microbeads in cutaneous wounds. *Am J Pathol* 2005;167:1519–29.
- [34] Lee SB, Kim YH, Chong MS, Hong SH, Lee YM. Study of gelatin-containing artificial skin V: fabrication of gelatin scaffolds using a salt-leaching method. *Biomaterials* 2005;26:1961–8.
- [35] Usha R, Ramasami T. The effects of urea and n-propanol on collagen denaturation: using DSC, circular dichroism and viscosity. *Thermochimica Acta* 2004;409:201–6.
- [36] Fei X, Seah CS, Lee ST. Human keratinocyte cell culture for the burns patients—a preliminary report. *Ann Acad Med Singapore* 1991;20:493–7.
- [37] Wang XQ, Liu PY, Kempf M, Cuttle L, Chang AH, Wong M, et al. Burn healing is dependent on burn site: a quantitative analysis from a porcine burn model. *Burns* 2009;35:264–9.

Rapid immunochromatographic test for serum granulysin is useful for the prediction of Stevens-Johnson syndrome and toxic epidermal necrolysis

Yasuyuki Fujita, MD,^a Naoya Yoshioka, MS,^a Riichiro Abe, MD, PhD,^a Junko Murata, MD, PhD,^a
Daichi Hoshina, MD,^a Hirokatsu Mae, MS,^b and Hiroshi Shimizu, MD, PhD^a
Sapporo, Japan

Background: Life-threatening adverse drug reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) sometimes start with clinical features of ordinary drug-induced skin reactions (ODSRs) and it may be difficult to make a correct diagnosis before severe mucocutaneous erosions occur. We have reported that serum granulysin levels are elevated (cut off: 10 ng/mL) in patients with SJS/TEN before generalized blisters form.

Objective: We sought to develop a rapid detection system for elevated serum granulysin to predict the progression from ODSRs.

Methods: Serum samples from 5 patients with SJS/TEN at 2 to 4 days before mucocutaneous erosions formed were analyzed. Sera from 24 patients with ODSRs and 31 healthy volunteers were also investigated as control subjects. We developed a rapid immunochromatographic assay for the detection of high levels of serum granulysin using two different antigranulysin monoclonal antibodies.

Results: The immunochromatographic test showed positive results for 4 of 5 patients with SJS/TEN but only one patient of 24 with ODSRs. The results correlated closely with those of enzyme-linked immunosorbent assays.

Limitations: The validation of the long-time stability in this test strip has not been investigated.

Conclusion: This novel test enables the prediction of SJS/TEN occurrence in patients even when only features of ODSRs are noted clinically. (J Am Acad Dermatol 2011;65:65-8.)

Key words: adverse drug eruption; diagnostic test; granulysin; Stevens-Johnson syndrome; toxic epidermal necrolysis.

Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are life-threatening adverse drug reactions characterized by blister formation and widespread skin detachment.¹ In the

Abbreviations used:

ODSRs:	ordinary drug-induced skin reactions
sFasL:	soluble Fas ligand
SJS:	Stevens-Johnson syndrome
TEN:	toxic epidermal necrolysis

From the Department of Dermatology, Hokkaido University Graduate School of Medicine,^a and Sapporo Immuno Diagnostic Laboratory.^b

The first two authors contributed equally to this article.

Funding sources: None.

Conflicts of interest: None declared.

Accepted for publication April 26, 2010.

Reprint requests: Riichiro Abe, MD, PhD, Department of Dermatology, Hokkaido University Graduate School of Medicine, N15 W7, Kita-ku, Sapporo 060-8638, Japan. E-mail: aberi@med.hokudai.ac.jp.

Published online April 20, 2011.

0190-9622/\$36.00

© 2010 by the American Academy of Dermatology, Inc.

doi:10.1016/j.jaad.2010.04.042

early stage, SJS/TEN presents clinically as edematous papules or erythema multiforme-like target rashes, which are very similar to those of ordinary drug-induced skin reactions (ODSRs). Such a clinical course makes it difficult to reach a diagnosis of SJS/TEN in the early stage, and this results in high mortality. There is an urgent need for a method to distinguish between early-stage SJS/TEN and ODSRs.

The method should be as fast as possible, because SJS/TEN usually occurs within a few days. Furthermore, the technique should be as clinically